This video is for instructional purposes only. The vaccine vials shown in this video may differ in appearance from actual vials of VAQTA.

VAQTA is indicated for active immunization against disease caused by hepatitis A virus in persons 12 months of age and older. Primary immunization should be given at least 2 weeks prior to expected exposure to hepatitis A virus.

Select safety information

VAQTA is contraindicated in individuals who are hypersensitive to any component of the vaccine. Hepatitis A vaccine should not be administered to persons with a history of a severe reaction to a prior dose of hepatitis A vaccine or to a vaccine component.

Individuals who develop symptoms suggestive of hypersensitivity after an injection of hepatitis A vaccine should not receive further injections of the vaccine.

In combined clinical trials involving healthy children 12 to 23 months of age and children and adolescents 2 to 18 years of age, the most commonly reported complaints (>2% of injections) in one or both of these groups were localized injection-site reactions (pain/tenderness/soreness, warmth, erythema, swelling), fever, diarrhea, vomiting, irritability, upper respiratory infection, rhinorrhea, cough, rash, otitis media, and headache.

The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.

As with any vaccine, vaccination with VAQTA may not result in a protective response in all susceptible vaccinees.

Before administering VAQTA, please read the Prescribing Information.

VAQTA is a registered trademark of Merck & Co., Inc.